NAV

Carbomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Carbomycin
DrugBank Accession Number
DB11383
Background

Carbomycin, also called magnamycin, is crystalline macrolide antibiotic. This antibacterial is obtained from Streptomyces halstedii and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains. The structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965.

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 841.9785
Monoisotopic: 841.445985101
Chemical Formula
C42H67NO16
Synonyms
  • Carbomicina
  • Carbomycin
  • Carbomycin A
  • Carbomycine
  • Carbomycinum
  • Magnamycin
  • Magnamycin A
External IDs
  • M 4209
  • M-4209
  • NSC-51001
  • NSC-55924
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Carbomycin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Carbomycin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Carbomycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Carbomycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Carbomycin.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
O-glycosyl compounds / Disaccharides / Tricarboxylic acids and derivatives / Fatty acid esters / Oxanes / Tertiary alcohols / Alpha-hydrogen aldehydes / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols
show 11 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aldehyde / Aliphatic heteropolycyclic compound / Alpha-hydrogen aldehyde / Amine / Amino acid or derivatives / Aminoglycoside core / Carbonyl group
show 26 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
AIK0XUF3AV
CAS number
4564-87-8
InChI Key
FQVHOULQCKDUCY-OGHXVOSASA-N
InChI
InChI=1S/C42H67NO16/c1-21(2)16-32(47)57-40-25(6)53-34(20-42(40,8)50)58-37-24(5)54-41(36(49)35(37)43(9)10)59-38-27(14-15-44)17-22(3)28(46)12-13-29-30(56-29)18-23(4)52-33(48)19-31(39(38)51-11)55-26(7)45/h12-13,15,21-25,27,29-31,34-41,49-50H,14,16-20H2,1-11H3/b13-12+/t22-,23-,24-,25+,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
IUPAC Name
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-(acetyloxy)-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
SMILES
[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@@H]3O[C@H]3C[C@@H](C)OC(=O)C[C@@H](OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C

References

General References
  1. HERRELL WE: Carbomycin. Int Rec Med Gen Pract Clin. 1955 Jul;168(7):463-72. [Article]
  2. MANNING PR, JONES PN, BIGHAM RS Jr: Clinical studies with carbomycin. N Engl J Med. 1953 Nov 5;249(19):758-61. [Article]
  3. Authors unspecified: MORE about carbomycin. N Engl J Med. 1953 Nov 5;249(19):784-5. [Article]
  4. HALLIDAY JA, ORMSBY HL: Carbomycin in ocular infections. Am J Ophthalmol. 1955 Jan;39(1):51-5. [Article]
  5. Ashy MA, Khalil AE, Abou-Zeid AA: Carbomycin, a macrolide antibiotic. Zentralbl Bakteriol Naturwiss. 1980;135(6):541-51. [Article]
  6. JUNG M: [Laboratory studies on carbomycin]. Lijec Vjesn. 1956 Mar-Apr;78(3-4):168-71. [Article]
  7. BERNHEIM M, JEUNE M, BETHENOD M, LEBRAT J: [Carbomycin in pediatric practice]. J Med Lyon. 1959 Feb 5;40(938):99-105. [Article]
  8. Authors unspecified: NEW AND nonofficial remedies: carbomycin. J Am Med Assoc. 1954 Aug 7;155(15):1335. [Article]
  9. HEWIT W: [Clinical and laboratory experience with carbomycin]. Dia Med. 1952 Dec 29;24(90):2335-8. [Article]
  10. PONS S: [Two antibiotics: magnamycin or carbomycin and tetracycline]. Minerva Med. 1955 Feb 28;46(17):567-8. [Article]
ChemSpider
4450165
ChEMBL
CHEMBL1231649
PDBe Ligand
CAI
Wikipedia
Carbomycin
PDB Entries
1k8a

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.115 mg/mLALOGPS
logP2.79ALOGPS
logP2.95Chemaxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.71Chemaxon
pKa (Strongest Basic)8.43Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count14Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area215.42 Å2Chemaxon
Rotatable Bond Count14Chemaxon
Refractivity208.45 m3·mol-1Chemaxon
Polarizability87.69 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-0000000090-bbffcdc87e06d6b1fe1a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0005-1000021940-13b85a72c74f0208085b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-0300100490-8e9957293ad5f38800b5
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9100012410-d928e5d5407393108cfa
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dl-3817200190-d087fe60efbea0b5950e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0096-8019251170-d87951d57eb7bf53d66d
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at February 25, 2016 18:18 / Updated at June 12, 2020 16:53